Immunotherapy for uterine malignancies

被引：0
作者：
de Gregorio, Nikolaus [1 ]
de Gregorio, Amelie [1 ]
机构：
[1] Univ Frauenklin Ulm, Prittwitzstr 43, D-89075 Ulm, Germany
来源：
GYNAKOLOGE | 2020年 / 53卷 / 04期
关键词：
Checkpoint inhibitors; Microsatellite instability; Endometrial cancer; Cervical cancer; Immunoncology; RECURRENT ENDOMETRIAL CARCINOMA; EXPRESSION; EFFICACY; SAFETY; TRIAL; PD-1;
D O I：
10.1007/s00129-019-04543-9
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
In contrast to ovarian cancer, where results have been rather disappointing so far, endometrial and cervical cancer seem to be promising targets for immunotherapy. This is due to human papillomavirus (HPV) infection in cervical cancer on one hand, and the microsatellite instability (MSI) frequently present in endometrial cancer on the other, both of which cause elevated immunogenicity in these tumors. In the USA, pembrolizumab has Food and Drug Administration (FDA) approval for both entities, i.e., for high-MSI or programmed cell death protein 1 ligand (PD-L1)-positive tumors. In addition, at the 2019 European Society for Medical Oncology (ESMO) meeting, promising results for combination therapies for both entities were presented.
引用
收藏
页码：238 / 242
页数：5
相关论文
共 20 条
  • [1] Signatures of mutational processes in human cancer
    Alexandrov, Ludmil B.
    Nik-Zainal, Serena
    Wedge, David C.
    Aparicio, Samuel A. J. R.
    Behjati, Sam
    Biankin, Andrew V.
    Bignell, Graham R.
    Bolli, Niccolo
    Borg, Ake
    Borresen-Dale, Anne-Lise
    Boyault, Sandrine
    Burkhardt, Birgit
    Butler, Adam P.
    Caldas, Carlos
    Davies, Helen R.
    Desmedt, Christine
    Eils, Roland
    Eyfjord, Jorunn Erla
    Foekens, John A.
    Greaves, Mel
    Hosoda, Fumie
    Hutter, Barbara
    Ilicic, Tomislav
    Imbeaud, Sandrine
    Imielinsk, Marcin
    Jaeger, Natalie
    Jones, David T. W.
    Jones, David
    Knappskog, Stian
    Kool, Marcel
    Lakhani, Sunil R.
    Lopez-Otin, Carlos
    Martin, Sancha
    Munshi, Nikhil C.
    Nakamura, Hiromi
    Northcott, Paul A.
    Pajic, Marina
    Papaemmanuil, Elli
    Paradiso, Angelo
    Pearson, John V.
    Puente, Xose S.
    Raine, Keiran
    Ramakrishna, Manasa
    Richardson, Andrea L.
    Richter, Julia
    Rosenstiel, Philip
    Schlesner, Matthias
    Schumacher, Ton N.
    Span, Paul N.
    Teague, Jon W.
    [J]. NATURE, 2013, 500 (7463) : 415 - +
  • [2] [Anonymous], 2019, ANN ONCOL, DOI DOI 10.1093/ANNONC/MDZ394.059
  • [3] [Anonymous], KREBS DEUTSCHL 2009
  • [4] Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601).
    Antill, Yoland Catherine
    Kok, Peey Sei
    Robledo, Kristy
    Barnes, Elizabeth
    Friedlander, Michael
    Baron-Hay, Sally E.
    Shannon, Catherine M.
    Coward, Jermaine
    Beale, Philip James
    Goss, Geraldine
    Meniawy, Tarek
    Yip, Sonia
    Smith, Deborah
    Spurdle, Amanda B.
    Parry, Michelle
    Andrews, John
    Kelly, Marzena
    Stockler, Martin R.
    Mileshkin, Linda R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Landscape of Microsatellite Instability Across 39 Cancer Types
    Bonneville, Russell
    Krook, Melanie A.
    Kautto, Esko A.
    Miya, Jharna
    Wing, Michele R.
    Chen, Hui-Zi
    Reeser, Julie W.
    Yu, Lianbo
    Roychowdhury, Sameek
    [J]. JCO PRECISION ONCOLOGY, 2017, 1 : 1 - 15
  • [6] Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
    Chung, Hyun Cheol
    Ros, Willeke
    Delord, Jean-Pierre
    Perets, Ruth
    Italiano, Antoine
    Shapira-Frommer, Ronnie
    Manzuk, Lyudmila
    Piha-Paul, Sarina A.
    Xu, Lei
    Zeigenfuss, Susan
    Pruitt, Scott K.
    Leary, Alexandra
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (17) : 1470 - +
  • [7] Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial
    Frenel, Jean-Sebastien
    Le Tourneau, Christophe
    O'Neil, Bert
    Ott, Patrick A.
    Piha-Paul, Sarina A.
    Gomez-Roca, Carlos
    van Brummelen, Emilie M. J.
    Rugo, Hope S.
    Thomas, Shari
    Saraf, Sanatan
    Rangwala, Reshma
    Varga, Andrea
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (36) : 4035 - +
  • [8] Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix
    Heeren, A. Marijne
    Punt, Simone
    Bleeker, Maaike C. G.
    Gaarenstroom, Katja N.
    van der Velden, Jacobus
    Kenter, Gemma G.
    de Gruijl, Tanja D.
    Jordanova, Ekaterina S.
    [J]. MODERN PATHOLOGY, 2016, 29 (07) : 753 - 763
  • [9] Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1
    Howitt, Brooke E.
    Shukla, Sachet A.
    Sholl, Lynette M.
    Ritterhouse, Lauren L.
    Watkins, Jaclyn C.
    Rodig, Scott
    Stover, Elizabeth
    Strickland, Kyle C.
    D'Andrea, Alan D.
    Wu, Catherine J.
    Matulonis, Ursula A.
    Konstantinopoulos, Panagiotis A.
    [J]. JAMA ONCOLOGY, 2015, 1 (09) : 1319 - 1323
  • [10] PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
    Le, D. T.
    Uram, J. N.
    Wang, H.
    Bartlett, B. R.
    Kemberling, H.
    Eyring, A. D.
    Skora, A. D.
    Luber, B. S.
    Azad, N. S.
    Laheru, D.
    Biedrzycki, B.
    Donehower, R. C.
    Zaheer, A.
    Fisher, G. A.
    Crocenzi, T. S.
    Lee, J. J.
    Duffy, S. M.
    Goldberg, R. M.
    de la Chapelle, A.
    Koshiji, M.
    Bhaijee, F.
    Huebner, T.
    Hruban, R. H.
    Wood, L. D.
    Cuka, N.
    Pardoll, D. M.
    Papadopoulos, N.
    Kinzler, K. W.
    Zhou, S.
    Cornish, T. C.
    Taube, J. M.
    Anders, R. A.
    Eshleman, J. R.
    Vogelstein, B.
    Diaz, L. A., Jr.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (26) : 2509 - 2520
12